Background and Purpose-We investigated the relationship between the degree of thrombus resolution and the time from stroke onset or thrombus formation to intravenous tissue-type plasminogen activator (tPA) treatment. Methods-In patients with stroke, we measured thrombus volume on thin-section noncontrast brain computed tomographic scans taken at baseline and 1 hour after tPA administration. We determined the association between the time from symptom onset to tPA treatment and the degree of thrombus resolution. In a C57/BL6 mouse model of FeCl 3 -induced carotid artery thrombosis, we investigated the effect of tPA administered at different time intervals after thrombus formation, using Doppler-based blood flow measurement. Results-Of 249 patients enrolled, 171 showed thrombus on baseline computed tomography. Thrombus was resolved by ≥50% in 43 patients (25.1%, good volume reduction) and by <50% in 94 patients (55.0%, moderate volume reduction) 1 hour after tPA treatment. In 34 patients (19.9%, nonvolume reduction; either no change or thrombus volume increased), overall thrombus volume increased. The probability of thrombus resolution decreased as the time interval from symptom onset to treatment increased. On multivariate analysis, good volume reduction was independently related with shorter time intervals from symptom onset to tPA treatment (odds ratio, 0.986 per minute saved; 95% confidence interval, 0.974-0.999). In the mouse model, as the interval between thrombus formation and tPA treatment increased, the initiation of recanalization was delayed (P=0.006) and the frequency of final recanalization decreased (P for trends=0.006). Conclusions-Early administration of tPA after stroke onset is associated with better thrombus resolution. 
T hrombolysis with intravenous tissue-type plasminogen activator (tPA) is a proven therapy for acute ischemic stroke when administered within 4.5 hours of symptom onset.
1,2 A previous meta-analysis and clinical trial data have demonstrated that the rapid administration of intravenous tPA is a key factor for better outcomes. 2, 3 In thrombolytic treatment, the concept that the earlier the treatment, the better the outcome is mostly based on the idea that the conversion of the ischemic penumbra to irreversible infarction is timedependent, and earlier reperfusion would increase the chance of saving potentially reversible brain areas. [4] [5] [6] The thrombus itself undergoes dynamic changes, and the architecture of fibrin in the thrombus changes rapidly during the process of thrombus formation. 7 In the initial stage of thrombus formation, fibrinogen binds to platelets, is accumulated at the lesion site, and forms a loose fibrin scaffold.
As time passes, fibrin fibers continue to accumulate and are packed tightly, and clots are retracted and stabilized. 8, 9 tPA exerts its fibrinolytic actions on the surface of the thrombus and by diffusion into the thrombus. Tightly packed fibrin fibers in the clot prohibit the diffusion of tPA, limiting its fibrinolytic action. 10 Thus, aged thrombi may be more resistant to tPA therapy than fresh thrombi. 11, 12 Consequently, the time from onset may affect not only the reversibility of the ischemic tissue damage but also the lysability of the thrombus in patients who receive tPA treatment. A recent study using transcranial Doppler suggested that the effect of tPA on recanalization may decrease over time. 13 However, it remains uncertain whether the degree of thrombus resolution differs according to the time interval between symptom onset or thrombus formation and the initiation of tPA treatment in patients with ischemic stroke.
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Recently, we demonstrated that the degree of thrombus resolution can be measured quantitatively using softwarebased thrombus volume assessment on thin-section noncontrast computed tomographic (NCCT) scans in patients with stroke 14, 15 and using Doppler-based real-time blood flow measurement in rodents. 16 In this study, we used these thrombus-measurement tools to investigate whether the degree of thrombus resolution differed (1) according to the time from symptom onset to intravenous tPA treatment in patients with stroke and (2) according to the time from the induction of thrombus formation to intravenous tPA treatment in mice.
Methods
Clinical Study Protocol
We retrospectively analyzed data in prospectively enrolled patients. For this study, we enrolled patients with acute ischemic stroke who were treated with intravenous tPA from 3 university hospitals between November 2006 and October 2009. One hospital (Yonsei University Stroke Center) continued the enrollment of patients until June 2013. Patients were treated with intravenous tPA (actylase; BoehringerIngelheim, Ingelheim, Germany) at a standard dose of 0.9 mg/kg (10% as bolus and then 90% as infusion for 60 minutes) within 3 hours after symptom onset, based on previous trials and stroke guidelines. 1, 17 Sequential intra-arterial treatment was allowed in patients who had an unsatisfactory clinical response at the end of intravenous tPA infusion (<50% improvement over baseline scores, according to the National Institutes of Health Stroke Scale). This study was approved by the institutional review board in each hospital, and all the patients or their qualified next of kin provided informed consent.
Imaging Protocol
NCCT was performed at baseline (before tPA treatment) and repeated at the end of tPA infusion (60 minutes after tPA bolus injection), using one of the multidetector row CT scanners at each hospital (Light Speed Plus; GE Medical Systems, Piscataway, NJ and Sensation 16; Siemens Medical Systems, Brilliance 64, Philips Medical Systems). Baseline and follow-up NCCT included both a 5-mm and either a 1.25-mm or 1-mm thin-section slice, according to a predetermined protocol (Methods in the online-only Data Supplement). The diagnosis of arterial thrombus increases with thinner CT slices and in the case of red thrombi; the sensitivity and specificity of 1.25-mm and 1-mm NCCT to diagnosis thrombus in the middle cerebral artery was reported as 100%. [18] [19] [20] When follow-up NCCT was performed, CT angiography was undertaken additionally to determine arterial occlusion.
Measurements of the Degree of Thrombus Resolution in Patients With Stroke
The volume and Hounsfield unit of the thrombus were measured using a 3-dimensional software package (Xelis, Infinitt, Seoul, Korea) on thin-section NCCT, by 2 independent neurologists (Y.D.K. and D.S.) who were blinded to the clinical information. More detailed information for thrombus measurement is described in Methods and Figure I in the online-only Data Supplement. After measurement of the thrombus volume on baseline and follow-up NCCTs, the degree of thrombus resolution (%) was calculated as ([initial thrombus volume−follow-up thrombus volume]/initial thrombus volume)×100. The inter-rater agreement of the volume and Hounsfield units of the thrombus was good, with an interclass coefficient of 0.981 for thrombus volume (P<0.001) and 0.950 for thrombus Hounsfield unit (P<0.001).
On the basis of the degree of change in the thrombus volume after intravenous tPA treatment, we divided the study population into 3 groups as follows: nonvolume reduction, whose thrombus volume increased or was not changed; moderate volume reduction, whose thrombus volume decreased by <50%; and good volume reduction, whose thrombus volume decreased by ≥50%, compared with the initial thrombus volume.
Clinical Variables
We prospectively collected demographics and medical or neurological data, as well as laboratory data (Methods in the online-only Data Supplement).
Experimental Study Protocol
Because the exact timing of thrombus formation is uncertain in patients with stroke, we investigated whether the response to intravenous tPA differed according to the time interval between thrombus formation and tPA treatment under experimental conditions using a mouse model. Under inhalation anesthesia with 5% isoflurane, we induced carotid artery thrombosis using FeCl 3 in 7-week-old male C57/BL6 mice and then administered intravenous tPA (9 mg/kg) at different time points (0, 0.5, 1, 2, or 3 hours) after thrombus formation was complete. The restoration of flow was assessed quantitatively using Doppler-based flow measurements. This animal model and the Doppler-based assessment system have been described previously 16 and in Methods in the online-only Data Supplement.
Outcome variables included (1) time to effective initial recanalization (time from tPA treatment to initial restoration of blood flow to ≥50% of baseline), (2) total duration of flow restoration (total time of blood flow ≥50% of baseline), and (3) final recanalization (flow restoration ≥50% of the baseline at 2 hours after tPA treatment). All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee of Yonsei University College of Medicine and were performed in strict accordance with the Association for Assessment and Accreditation of Laboratory Animal Care.
Statistical Analyses
Statistical analyses were performed using the Windows IBM SPSS software package (version 21.0, Chicago, IL) or R software package version 3.0.1 (http://www.R-project.org). Continuous variables were compared using independent-sample t tests, Mann-Whitney tests, Kruskal-Wallis tests, or ANOVA, whereas categorical variables were compared using χ 2 tests, Fisher exact tests, or the MantelHaenszel test, as appropriate. Post hoc analyses were conducted using Bonferroni test. The relationship between the probability of a decrease in thrombus volume according to the interval (minutes) from stroke onset to intravenous tPA treatment was expressed using the B-spline curve. Cubic spline curve was also obtained to show additional insights into the linearity of the association between the thrombus volume reduction and the interval from symptom onset to intravenous tPA treatment in the total sample. To determine independent factors for good volume reduction to intravenous tPA therapy, multinomial regression analysis was used to compute the odds ratios of covariates that showed P<0.05 in univariate analysis. A P value <0.05 was considered statistically significant, but for post hoc analyses using Bonferroni correction, 3×raw P value <0.05 (2-tailed test) was needed for statistical significance.
Results
Baseline Characteristics
During the study period, a total of 249 patients underwent NCCT based on our study protocol. After the exclusion of 5 patients because of poor image quality and 1 patient whose symptoms proved to be of nonstroke origin, 243 patients were included in this study. Among these 243 patients, thrombi were detected in 171 patients (70.4%; Figure II in the online-only Data Supplement). Compared with the patients without a thrombus (n=72), those with a thrombus were more likely to be women, and to have atrial fibrillation, low platelet counts, and total cholesterol levels, cardioembolism or larger artery atherosclerosis, and history of calcium channel blocker treatment (Table I in the online-only Data Supplement).
Among the 171 patients with a thrombus, the mean age was 67.2±12.1 years (median, 69; interquartile range [IQR], 59-75) and 45% were men. The occlusion site was most commonly in the middle cerebral artery M1 segment (46.2%; n=79), followed by the distal internal carotid artery (26.9%; n=46), middle cerebral artery M2 segment (18.1%; n=31), basilar artery (7.0%, n=12), and posterior cerebral artery (1.8%; n=3). The median initial National Institutes of Health Stroke Scale score was 16 (IQR, [12] [13] [14] [15] [16] [17] [18] [19] . Compared with the good volume reduction to intravenous tPA, moderate or nonvolume reduction had higher initial National Institutes of Health Stroke Scale scores and was more likely to receive sequential intra-arterial reperfusion treatment (Table II in 
Changes in Thrombus Volume After Intravenous tPA Infusion
The mean times measured from stroke onset were 74.7±35.8 (median, 67; IQR, 46-98) minutes to baseline CT and 104.6±38.5 (median, 100; IQR, 75-133) minutes to intravenous tPA. The mean time from intravenous tPA to follow-up CT was 58.7±18.0 minutes. On the follow-up CT, 137 of 171 (80.1%) patients showed some degree of thrombus resolution: 43 (25.1%) were good volume reduction (median volume reduction, 86.2%; IQR, 60.1%-100%), and 94 (55.0%) were moderate volume reduction (median volume reduction, 17.9%, IQR, 8.5%-30.5%). The thrombus was completely lysed in 16 (9.4%) patients. However, the thrombus volume was noted to have increased (median volume reduction, −13.5%; IQR, −44.6% to −6.0%) in 34 (19.9%) patients after intravenous tPA treatment (nonvolume reduction).
As the time (in intervals of 30 minutes) from stroke onset to intravenous tPA treatment increased, the proportion of nonvolume reduction increased, whereas that of good and moderate volume reduction decreased (P for trends=0.028; Figure 1 ). The univariate B-spline curve showed that the probability of thrombus resolution was inversely associated with the time (per 1 minute) from stroke onset to intravenous tPA treatment ( Figure 2 ).
Factors Associated With Thrombus Resolution
We investigated the factors that were associated with the degree of thrombus resolution. Univariate analysis showed that good volume reduction was associated with atrial fibrillation, previous antiplatelet use, smaller initial thrombus volume, lower initial National Institutes of Health Stroke Scale scores, and a shorter time interval from symptom onset to intravenous tPA treatment (Table II in the online-only Data Supplement). We performed multivariate analysis to determine the independent factors associated with thrombus resolution. After adjustment for significant factors on univariate analysis, good volume reduction to intravenous tPA therapy was independently related to a shorter time interval from symptom onset to intravenous tPA treatment (Table) . When the study group was dichotomized into 2 groups, such as nonvolume reduction versus volume reduction group, the treatment time was also independently associated with nonvolume reduction (Table III in the online-only Data Supplement). Cubic spline curve based on univariate (unadjusted) and multivariate (adjusted) logistic regression models also demonstrated the inverse and linear relationship between the time (per 30 minutes) from symptom onset to treatment time ( Figure III in the online-only Data Supplement). In terms of recanalization based on thin-section NCCT and follow-up CT angiography, reopening of the initial occlusion site was achieved in 32 patients; 16 patients had complete recanalization without thrombus, and 16 had the partial recanalization with distal migration and thrombus volume reduction (n=13) or with some residual thrombus/stenosis (n=3) on CT angiography. When the study population was dichotomized into 2 groups such as nonrecanalization (n=139) and the recanalization group defined as having a Thrombolysis In Myocardial Infarction grade of ≥2 (n=32), the recanalization was associated with the shorter time interval from symptom onset to intravenous tPA treatment (P=0.043). On multivariate analysis adjusting for significant variables (P<0.05) on univariate analysis, the shorter time interval from symptom onset to tPA treatment showed a trend for the recanalization (Table IV in the online-only Data Supplement). . Among these 12 mice with flow restoration, the mean time from intravenous tPA to effective initial recanalization was 31.6±22.2 minutes; the mean time differed significantly according to the time from thrombus formation to intravenous tPA administration (17.6±5.0 minutes in the 0-hour group, 27.0±10.4 minutes in the 0.5-hour group, and 61.0±25.7 minutes in the 1-hour group; P for trends=0.006; Figure 3A and 3C). The total duration of flow restoration increased according to how soon the intravenous tPA treatment was applied (P for trends<0.001; Figure 3B and 3D). At 2 hours after intravenous tPA treatment, final recanalization was achieved in 4 of the 5 mice in the 0-hour group, 2 of the 5 mice in each of the 0.5-and 1-hour groups, and none of the 10 mice in the 2-hour and 3-hour groups. A strong positive relationship was also observed between final recanalization and the time from thrombus formation to the intravenous tPA treatment (P for trends=0.006).
Discussion
In this study, we investigated the relationship between the degree of thrombus dissolution and the time from the symptom onset or thrombus formation to the initiation of intravenous tPA treatment. Although a recent study using transcranial Doppler showed that intravenous tPA treatment after 270 minutes of symptom was associated with a lower recanalization rate, 13 no data are available on the relationship between the quantitative changes in thrombus volume and the interval from symptom onset to intravenous tPA treatment in patients with acute ischemic stroke. Our previous work suggested a decrease in the extent of thrombus resolution as treatment time increases, although it was not statistically significant. 14 This study demonstrated inverse, linear relationship between the degree of thrombus resolution after tPA treatment and the time from symptom onset to treatment.
The architecture of a thrombus experiences rapid and dynamic changes, which may affect its lysability with tPA treatment as follows. 21 Initially, low levels of thrombin form a fresh thrombus with a porous fibrin scaffold, and at this stage, a clot is easily resolved by tPA. Subsequently, the thrombus is stabilized, as fibrins accumulate, and fibrin fibers are crosslinked by factor XIII. At this stage, the thrombus becomes more compact and has smaller pores. This results in lower penetration of tPA, limiting its fibrinolytic action within the thrombus. 7, 22, 23 Previous semiquantitative histological analyses of thrombi obtained by thromboaspiration from the coronary artery have shown that the fibrin content of the thrombus increases over several hours in patients with ST-segmentelevation myocardial infarction. The time-dependent changes in the thrombus may affect the efficacy of thrombolytic treatment, as observed in our results.
In the clinical setting, the time of symptom onset may not be the same as that of thrombus formation. Under certain conditions, such as chronic atrial fibrillation, the thrombus may exist in the heart for many hours or days before embolic events develop. 24 In this context, our analysis in patients with stroke, which was based on symptom onset, has an inevitable limitation. Therefore, we performed further experiments using an FeCl 3 -induced thrombosis model in mice, which is well established in thrombosis research, 25 to better determine whether the thrombolytic effect of tPA actually decreases as the time interval from thrombus formation to tPA administration increases. FeCl 3 produces thrombosis in the vessel by free radical injury to the artery's endothelium and smooth muscle layer. 25 We have previously shown that the size of thrombus formed by FeCl 3 treatment was similar among animals in this model and that the degree of blood flow restoration, as measured by ultrasound, is a good representation of thrombus resolution. 16 Although it has been suggested that an aged thrombus would be resistant to tPA treatment, this concept remains understudied in vivo. 10 This study, using a thrombosis model in mice, clearly demonstrated that the effect of tPA is dependent on the age of the thrombus. However, in this mouse model, blood flow restoration by tPA treatment was not observed at 2 hours and beyond after thrombotic occlusion, which is an earlier time interval than that expected in humans. This is possibly because oxidative stress, as induced by FeCl 3 , produces changes in fibrin structure that result in less efficient plasminogen activation by tPA. 26 FeCl 3 produces platelet-rich thrombi, 27 which are more likely to be resistant to tPA, and rodents and human have different PA systems.
In this study, only 9.4% of patients showed complete resolution of the thrombus, a lower rate than that in previous reports using transcranial Doppler or angiographic studies. 28, 29 This might be ascribed to the early documentation of thrombus resolution in this study. There is a latent time until clot lysis after tPA administration; however, in this study, the average interval from tPA administration to follow-up CT was ≈60 minutes. In a previous study using transcranial Doppler, the mean time until the beginning of recanalization was ≈23 minutes after tPA administration. 30 This was also reproduced in the mouse model in our study, where there was a time lag of ≈32 minutes until the effective restoration of blood flow (flow restoration, ≥50% of baseline) after tPA treatment, if recanalization was achieved.
In this study, thrombus volume increased in 20% of the patients despite tPA treatment. This suggests that thrombus in some patients does not respond to intravenous tPA. tPA may paradoxically increase thrombogenicity by activating platelets and thrombin and releasing plasminogen activator inhibitor-1 and α 2 -antiplasmin. 31, 32 Thus, in the case of resistant thrombi, thrombus volume might be paradoxically increased by tPA treatment.
This study has certain limitations. First, a follow-up CT was obtained only once, probably, whereas tPA was still exerting its fibrinolytic action. This led to our detection of a low rate of complete thrombus resolution, as mentioned above. In addition, the process of thrombus dissolution during thrombolytic treatment may be dynamic, with frequent thrombolysis and rethrombosis occurring during or immediately after thrombolytic treatment. 16, 33 This was also observed during the real-time monitoring of blood flow in the mice in our experimental study, with frequent alternate reocclusion and reperfusion during or immediately after tPA infusion. Therefore, the thrombus volume, which was measured based on a onetime snapshot CT image, may be insufficient for assessing the entire process of thrombus dissolution after tPA treatment.
Second, although the FeCl 3 -induced thrombosis model, as used in this study, produces thrombi with a rather homogenous and platelet-rich composition which are more likely observed in symptomatic plaques of the large artery atherosclerosis subtype, stroke can be caused by thrombotic occlusions with heterogeneous causes and composition. Third, time-dependent thrombus resolution may exist even in the absence of intravenous tPA treatment, although we could not investigate it in this population. Fourth, some patients with thrombus being on spontaneously lysis may be misinterpreted as one having good response to intravenous tPA treatment. Finally, we could not assess the relationship between the clinical outcome and the thrombus resolution because many patients received additional intra-arterial therapy, although it is of value clinically to show the relationship between clinical improvement and the thrombus resolution, which contemplates a surrogate marker for recanalization.
Conclusions
This study demonstrated that the degree of thrombus resolution after intravenous tPA treatment decreases as the age of the thrombus and the time from symptom onset to intravenous tPA treatment increase. The catchphrase time is brain has been used to emphasize that reducing the time interval from symptom
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onset to thrombolytic treatment is crucial because without restoration of blood flow, neurons continue to die over time. Our findings also indicate that the likelihood of a thrombus being resolved by tPA treatment decreases with increasing time from thrombus formation. Earlier administration of tPA after stroke onset is important not only for brain salvage but also for better thrombus resolution. In this context, time is clot, as well as brain should be the catchphrase for thrombolytic treatment. Table IV If the thrombus was separated, the volumes of all component thrombi were summed.
Sources of Funding
To determine the HU value of the thrombus, the HU of the culprit thrombus was standardized to the HU value of the contralateral normal M1 segment of the middle cerebral artery (MCA):
corrected HU of the thrombus (HU corrected) = mean HU contralateral × (HU ipsilateral / HU contralateral). When any artery other than the MCA was occluded, the HU of the normal M1 segment was used for standardization, since the HU of the normal basilar artery and that of the normal MCA are known to be well correlated. 
Clinical variables
We collected the patients' data in the following categories: vascular risk factors, including hypertension, diabetes mellitus, hyperlipidemia, and current smoking (any cigarette smoking within 1 year prior to admission); the presence of atrial fibrillation, valvular heart diseases, congestive heart failure, ischemic heart disease, or peripheral arterial occlusive diseases; and history of prior medication. Systolic and diastolic blood pressures on admission and laboratory findings, including lipid profile data, hemoglobin levels, white blood cell counts, platelet counts, blood sugar levels, prothrombin time, and activated partial prothrombin time, were also recorded.
The underlying mechanism of stroke was determined based on the classification in the Trial of ORG 10172 in Acute Stroke Treatment. 2 The intervals (min) from stroke onset to admission, baseline CT, and IV t-PA treatment were calculated for each patient. Stroke severity was assessed using the NIHSS.
Experimental study protocol
For operative procedures, 7-week-old male C57/BL6 mice weighing 22-24 g were anesthetized by inhalation of 5% isoflurane in a mixture of 70% N 2 O and 30% O 2 . After shaving and sterile preparation of the animal, the left common carotid artery (CCA) was carefully dissected under a surgical microscope via a midline incision on the neck. An ultrasonic Doppler flow probe (MA0.7PSB; Transonic Instruments, Ithaca, NY, USA) was placed around the mid-portion of the CCA. Carotid blood flow was monitored with a Transonic TS420 Blood Flow Meter (Transonic Instruments, Ithaca, NY, USA), and blood flow data were obtained using an iWorx IX-304T data acquisition system (iWorx Systems, Inc., Dover, NH). Baseline flow in the CCA was measured for 5 min before the ultrasonic Doppler flow probe was removed. After the surface of the CCA had been dried by removal of tissue fluid from its surface and from around it, a filter paper (700 × 800 μm) saturated with 50% FeCl 3 was placed on the adventitial surface of the midpoint of the exposed CCA for 5 min. After removal of the filter paper, the CCA was washed with normal saline and its blood flow was recorded by the ultrasonic Doppler flow probe. Successful occlusion was defined as the absence of blood flow on Doppler, maintained for 10 min. t-PA was administered at 0, 0.5, 1, 2, or 3 h after the completion of thrombotic occlusion, with a 10% bolus injection followed by continuous infusion of the remaining dose for 1 h via the left femoral vein, using an infusion pump (KDS100 syringe pump; KD Scientific, Holliston, MA, USA) connected to PE-10 tubing. For this experiment, 5 mice were used in each group (total = 25 mice) and 9 mg/kg t-PA, i.e., a 10-fold higher dose than that administered to humans, was administered.
PA systems differ between humans and rodents, and it has been shown that approximately 10-fold higher doses of t-PA are necessary in rodents in order to achieve fibrinolytic effects similar to those in humans. 3, 4 We have also previously demonstrated that this dose of 9 mg/kg t-PA is optimal in this model for achieving the desired thrombolytic effect. 5 Carotid blood flow was monitored continuously for 2 h from the initial time of t-PA administration. 
Supplemental
Supplemental Figure I. Measurement of thrombus characteristics
The volume of the thrombus detected by thin-section non-contrast CT was measured using a three-dimensional software package (Xelis, Infinitt, Seoul, Korea). 
